Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/1b, Open-Label Study of the Pressure-Enabled Hepatic Artery Infusion of SD-101, a TLR9 Agonist, Alone or in Combination With Intravenous Checkpoint Blockade in Adults With Metastatic Uveal Melanoma

Next Previous
X
Search
Trial Profile

A Phase 1/1b, Open-Label Study of the Pressure-Enabled Hepatic Artery Infusion of SD-101, a TLR9 Agonist, Alone or in Combination With Intravenous Checkpoint Blockade in Adults With Metastatic Uveal Melanoma

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Nelitolimod (Primary) ; Nivolumab (Primary) ; Nivolumab/relatlimab (Primary)
  • Indications Liver metastases; Uveal melanoma
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms (PERIO)-01; PERIO-01
  • Sponsors TriSalus Life Sciences

    • Most Recent Events

    • 15 Aug 2024 According to a TriSalus Life Sciences media release, final results for the PERIO-01 Phase 1 trial are expected in Q4 2024.
    • 21 Dec 2023 Status changed from recruiting to active, no longer recruiting.
    • 06 Nov 2023 Results presented in a MD Anderson Cancer Center Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top